Perez, who suffers from the degenerative joint disease
osteoarthritis, took part in a clinical trial designed to test the
efficacy of arthroscopic surgery on osteoarthritic knees, and has been
pain-free for more than two years since.
The interesting thing, though, is that Perez was in the "sham
surgery" group of the study and the researchers did almost nothing to
him.
Osteoarthritis, which afflicts more than 20 million Americans, is
characterized by the breakdown of cartilage in the joints. Oral
medications as well as lifestyle changes can treat the disease, but for
some patients, arthroscopic surgery — in which damaged cartilage is
scraped or flushed out with the aid of a thin viewing scope — is also an
option.
Perez was assigned to the placebo group of the trial: He was given
anesthesia and doctors made incisions in his knee so that it looked as
though he had an arthroscope inserted. This sham surgery group was
compared to other patients who underwent an actual arthroscopic
procedure.
The study, published this week in the New England Journal of
Medicine, found some surprising results.
"The groups were all reporting improvement; it's just there was no
greater benefit in any of the groups compared to the placebo," Dr. Bruce
Moseley, lead author of the study and clinical associate professor of
orthopedic surgery at Baylor College of Medicine in Houston, told
ABCNEWS' Jackie Judd.
This experience has left Perez with a strong understanding of the
placebo effect and of how belief that a surgery can relieve pain may
actually do just that. "It's a mental thing," he said. "I think that if
you believe in something, you can get well."
And for the medical community, it has led to the understanding that
arthroscopic surgery, as performed an estimated 200,000 times a year for
the treatment of osteoarthritic knees, may be useless. "My opinion is we
probably shouldn't be doing it," said Moseley.
Suspicions Confirmed
For some physicians who share Moseley's opinion, this new study
confirms their suspicions.
"It's my impression that arthroscopy in the osteoarthritic patient
has already become less popular primarily because it hasn't had the
benefits that people thought it would," said Dr. William W. Tipton Jr.,
executive vice president and CEO of the American Academy of Orthopedic
Surgeons in Rosemont, Ill.
It was believed that the often considerable pain associated with the
condition could be improved surgically through flushing out and removing
cartilage debris in the knee joint.
"Practically every report, every study that was ever done said that
the majority of patients were improved after they had the surgery," said
Moseley. "It's just that nobody ever said they were well. It was clear
that many of these patient's early improvement would digress over time
and they would end up with [knee] replacement surgery."
The Power of Placebo
Up until now, no one had tested this surgical procedure against a
placebo or "sham surgery" to ferret out how much of the improvement seen
following surgery is due to what the surgery actually does or to the
placebo effect.
"Any treatment for pain has an enormous placebo effect," said Dr.
Gary Firestein, chairman of the Food and Drug Administration's Arthritis
Advisory Committee and chief of rheumatology, allergy and immunology at
the University of California at San Diego School of Medicine. "The
response rates are generally in the 20 to 40 percent range for almost
all studies, and higher percentages are associated with more aggressive
and invasive approaches where the belief system is firmly entrenched."
That highlights the importance of conducting placebo-controlled
trials for surgical procedures, but that undertaking involves
considerable ethical issues due to the invasive nature of surgery. For
example, questions about the ethics of sham surgery were raised
following a study on surgical implantation of fetal cells to treat
Parkinson's disease. All subjects had holes bored into their skulls, but
only half were given any treatment with the cells.
The more benign nature of arthroscopy has lent itself to less
criticism. Many experts agree that the design of the current study was
fair by ethical standards and that in this case it was important to
determine whether such a common procedure was indeed effective.
"More important is whether it was ethical to perform tens of
thousands of these invasive procedures on patients without any
documentation that it alters the natural history of disease, quality of
life or functional outcome," said Firestein.
Effect on Practice and Policy
Because this is the first such placebo-controlled study on
arthroscopy for osteoarthritis, it is too soon to say whether the
findings of the study will have any major impact on insurance coverage
or physician practice.
Aetna, one of the nation's largest health-insurance providers,
currently covers the procedure and says it plans to have its medical
directors review the information before it considers making any changes
in coverage.
Other experts would like to see the results duplicated before
instituting widespread changes. "I think this is an interesting study …
I'd like to have a couple of other centers repeat [it]," said Tipton.
One issue that remains is whether these findings would hold true for
women, as the current study was conducted only in men. "Since
osteoarthritis of the knee is more prevalent in women than in men, it is
not clear that patients in the community always fit the study criteria
precisely," said Firestein.
As for Perez, no matter what future research may find, he is happy
with how everything has worked out. "I can dance, I can go away fishing,
I can play basketball and it doesn't bother me one bit. Everything is
wonderful."

|